أرسل هذا في رسالة قصيرة: Impact of ixazomib-lenalidomide-dexamethasone therapy on overall survival in multiple myeloma patients: Analysis of the emerging-markets subgroup of the TOURMALINE-MM1 trial.

  _____     _____              __   __  __    __  
 /  ___||  |  ___||   ____     \ \\/ // \ \\ / // 
| // __    | ||__    |    \\    \ ` //   \ \/ //  
| \\_\ ||  | ||__    | [] ||     | ||     \  //   
 \____//   |_____||  |  __//     |_||      \//    
  `---`    `-----`   |_|`-`      `-`'       `     
                     `-`